A significant decrease in ALT levels in the blood and a downregulation in hepatic senescence marker gene p16INK4a, which drives the phenotype of NAFLD33 suggest the possibility of suppressing the progression of NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.